Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation

Blood Adv. 2022 May 24;6(10):3058-3061. doi: 10.1182/bloodadvances.2021006535.

Authors

Sanyukta Janardan^{1

2}, Edwin Horwitz^{1

2}, Benjamin Watkins^{1

2}, Kirsten Williams^{1

2}, Shanmuganathan Chandrakasan^{1

2}, Muna Qayed^{1

2}, Suhag Parikh^{1

2}, Staci Arnold^{1

2}, Frank Keller^{1

2}, Adina Alazraki³, Michelle Schoettler^{1

2}, Kathryn Leung^{1

2}

Affiliations

¹ Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
² Children's Healthcare of Atlanta, Atlanta, GA; and.
³ Department of Radiology, Emory University School of Medicine, Atlanta, GA.

No abstract available

MeSH terms

Antibodies, Bispecific* / adverse effects
Hematopoietic Stem Cell Transplantation* / adverse effects
Remission Induction

Substances

Antibodies, Bispecific
blinatumomab